Search

Antithrombin Alfa

Antithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations

Pyrophosphoric acid

Promestriene

Promestriene has been studied in phase IV of the clinical trial on improvement of hormonal cytology, local and systemic climacteric complaints, as well as its endometrial security in patients with vaginitis … In addition, promestriene was in phase IV of the clinical trial to study its treatment of patients with vaginosis, bacterial, but that studied was terminated.

Spectinomycin

An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.

APD668

APD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated

Indalpine

Indalpine was one of the first selective serotonin reuptake inhibitors to reach the American market. It was initially marketed by Pharmuka. … However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market.

Oleoyl-estrone

It has been shown in animal studies to promote the loss of body fat while maintaining body protein storage, maintaining nitrogen balance. … This hormone occurs naturally and is found circulating in various animal species and humans.

Iobenguane

FDA approved on September 19, 2008.

Adakitug

HuMax-Inflam was also effective in reducing disease activity in palmoplantar pustulosis patients in a clinical study. … In pre-clinical studies, HuMax-Inflam has been shown to inhibit tumor growth in tumor models using primary human tumors in immunodeficient mice.

Pomaglumetad methionil

LY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. … Further studies are planned or are ongoing to learn more about the safety and effectiveness, including determining an optimal therapeutic dose for LY2140023.